Skip to main content
. 2022 Apr 21;13:2169. doi: 10.1038/s41467-022-29857-6

Fig. 1. Establishment and histological characterization of PDPCOs.

Fig. 1

a Overview of the study. A total of 84 PDPCO lines, including PDAC, NEN, IPMN and ACC, were established by samples obtained by surgery or EUS-FNA. Original tissues were used for histological examination and WES/panel sequencing. PDPCOs were subjected to engraftment, histological examination, WGS/WES, RNA-seq, ATAC-seq and drug screening. b Representative brightfield image of PDPCOs generated from normal pancreas, PDAC, IPMN, NEN and ACC tissue. Scale bar, 200 μm. Experiments are repeated at least three times with similar results. c, Representative H&E staining of PDAC primary tumors, organoids, and xenografts (CAS-DAC-13, CAS-DAC-29 and CAS-DAC-30). Scale bar, 50 μm. Experiments are repeated at least three times with similar results. d Representative H&E and alcian blue staining of an IPMN primary tissue, organoid and xenograft (CAS-IPMN-1). Scale bar, 50 μm. Experiments are repeated at least three times with similar results. e Representative H&E, SYP, CHGA and Ki67 staining of NEN primary tissues, organoids and xenografts (CAS-NEN-2 and CAS-NEN-4). CAS-NEN-2 was clinically diagnosed as WHO grade G2, while CAS-NEN-4 was diagnosed as NEC. Scale bar, 50 μm. Experiments are repeated at least three times with similar results. PDPCO, patient-derived pancreatic cancer organoid; PDAC, pancreatic ductal adenocarcinoma; NEN, pancreatic neuroendocrine neoplasm; IPMN, intraductal papillary mucinous neoplasm; ACC, acinar cell carcinoma; EUS-FNA, endoscopic ultrasound-guided fine needle aspiration biopsy.